London & Capital Asset Management’s AbbVie ABBV Stock Holding History

London & Capital Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.37M	Buy	5,460 +264	+5%	+$56.8K	0.01%	99
2026 Q1	$1.13M	Sell	5,196 -310	-6%	-$68.8K	0.01%	107
2025 Q4	$1.26M	Buy	+5,506	New	+$1.25M	0.01%	114
2022 Q1	–	Sell	-12,883	Closed	-$1.74M	–	69
2021 Q4	$1.74M	Sell	12,883 -35	-0.3%	-$4.13K	0.11%	55
2021 Q3	$1.39M	Buy	+12,918	New	+$1.48M	0.1%	57
2021 Q2	–	Sell	-11,979	Closed	-$1.3M	–	82
2021 Q1	$1.3M	Buy	11,979 +1,391	+13%	+$149K	0.12%	60
2020 Q4	$1.14M	Buy	+10,588	New	+$1.02M	0.13%	56
2020 Q3	–	Sell	-6,596	Closed	-$648K	–	61
2020 Q2	$648K	Buy	6,596 +1,000	+18%	+$88K	0.11%	55
2020 Q1	$426K	Hold	5,596	–	–	0.1%	56
2019 Q4	$495K	Buy	5,596 +36	+0.6%	+$2.99K	0.08%	69
2019 Q3	$421K	Sell	5,560 -2,412	-30%	-$165K	0.07%	67
2019 Q2	$580K	Buy	7,972 +5,079	+176%	+$399K	0.12%	64
2019 Q1	$233K	Buy	2,893 +246	+9%	+$20.1K	0.04%	80
2018 Q4	$244K	Buy	+2,647	New	+$233K	0.04%	77

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

London & Capital Asset Management's ABBV Position: Q2 2026 in Review

London & Capital Asset Management increased its AbbVie (ABBV) stake by 5.1% in Q2 2026, buying an estimated $56.8K and bringing the position to 5,460 shares worth $1.37M. The position accounts for 0.01% of the portfolio, ranked #99.

London & Capital Asset Management first reported a position in ABBV in Q4 2018 and has held it in 14 quarters since. The position peaked at $1.74M in Q4 2021. 4,236 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

London & Capital Asset Management held 5,460 shares of AbbVie worth $1.37M as of Q2 2026.
London & Capital Asset Management bought 264 AbbVie shares in Q2 2026, an estimated $56.8K.
AbbVie made up 0.01% of London & Capital Asset Management's portfolio in Q2 2026, its #99 holding.
London & Capital Asset Management first reported a position in AbbVie in Q4 2018 and has held it in 14 quarters since.
London & Capital Asset Management's AbbVie position peaked at $1.74M in Q4 2021.
4,236 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on London & Capital Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.